<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01136538</url>
  </required_header>
  <id_info>
    <org_study_id>07-VIN-028</org_study_id>
    <nct_id>NCT01136538</nct_id>
  </id_info>
  <brief_title>Bioavailability Study of Valacycovir HCl Tablets, 1000 mg of Dr. Reddy's Under Fed Condition</brief_title>
  <official_title>An Open Label, Balanced, Randomized, Two Treatment, Two-sequence, Two-period, Single-dose Crossover Comparative Bioavailability Study of 1000 mg Valacyclovir HCl Tablets of Dr. Reddys's and Valtrex (R) 1 gm Caplets of GlaxoSmithkline in Healthy Volunteers Under Fed Conditions.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. Reddy's Laboratories Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dr. Reddy's Laboratories Limited</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to&#xD;
&#xD;
        1. Compare and evaluate the single-dose bioavailability study of 1000mg Valacyclovir HCl&#xD;
           tablets of Dr. Reddy's and Valtrex (R)(Valacyclovir Hydrochloride)CAPLETS 1 gram of&#xD;
           GlaxoSmithkline, in healthy, adult human subjects under fed conditions.&#xD;
&#xD;
        2. monitor the adverse events and ensure the safety of subjects.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      An open label, balanced, randomized, two-treatment, two-sequence two-period, single-dose,&#xD;
      crossover comparative bioavailability study of 1000 mg Valacyclovir Hydrochloride Tablets of&#xD;
      Dr. Reddy's Laboratories Ltd., India and valtrex (R) (Valacyclovir Hydrochloride) CAPLETS 1&#xD;
      gram of GlaxoSmithkline in healthy, adult human subjects under fed conditions&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2007</start_date>
  <completion_date type="Actual">May 2007</completion_date>
  <primary_completion_date type="Actual">February 2007</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bioequivalence based on Cmax and AUC parameters</measure>
    <time_frame>4 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">34</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Valacyclovir Hydrochloride</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Valacyclovir Hydrochloride Tablets, 1000 mg of Dr. Reddy's Laboratories Limited</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Valtrex (R)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Valtrex (R) (Valacyclovir Hydrochloride) CAPLETS 1 gram of GlaxoSmithkline</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Valacyclovir Hydrochloride</intervention_name>
    <description>Valacyclovir Hydrochloride Tablets, 1000 mg of Dr. Reddy's Laboratories Limited</description>
    <arm_group_label>Valacyclovir Hydrochloride</arm_group_label>
    <arm_group_label>Valtrex (R)</arm_group_label>
    <other_name>Valtrex (R)(Valacyclovir Hydrochloride) CAPLETS 1 gm</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        The subjects were selected for study participation, based on the following criteria:&#xD;
&#xD;
          1. Human subjects aged between 18 and 45 years (including both).&#xD;
&#xD;
          2. Subjects' weight within the normal range according to normal values for the Body Mass&#xD;
             Index (18.5 to 24.9 kg/m2) with minimum of 50 kg weight.&#xD;
&#xD;
          3. Subjects with normal health as determined by personal medical history, clinical&#xD;
             examination and laboratory examinations within the clinically acceptable normal range.&#xD;
&#xD;
          4. Subjects having normal 12-lead electrocardiogram (ECG).&#xD;
&#xD;
          5. Subjects having normal chest X-Ray (PIA view).&#xD;
&#xD;
          6. Have a negative urine screen for drugs of abuse (including amphetamines, barbiturates,&#xD;
             benzodiazepines, marijuana, cocaine, and morphine).&#xD;
&#xD;
          7. Have negative alcohol breath test.&#xD;
&#xD;
          8. Subjects willing to adhere to the protocol requirements and to provide written&#xD;
             informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        The subjects were excluded from the study, based on the following criteria:&#xD;
&#xD;
          1. Hypersensitivity to Valacyclovir Hydrochloride or related drugs.&#xD;
&#xD;
          2. History or presence of significant cardiovascular, pulmonary, hepatic, renal,&#xD;
             gastrointestinal, endocrine, immunological, dermatological, neurological or&#xD;
             psychiatric disease or disorder.&#xD;
&#xD;
          3. History or presence of significant alcoholism or drug abuse in the past one year.&#xD;
&#xD;
          4. History or presence of significant smoking (more than 10 cigarettes or beedi' s/day).&#xD;
&#xD;
          5. History or presence of significant asthma, urticaria or other allergic reactions.&#xD;
&#xD;
          6. History or presence of significant gastric and/or duodenal ulceration.&#xD;
&#xD;
          7. History or presence of significant thyroid disease, adrenal dysfunction, organic&#xD;
             intracranial lesion such as pituitary tumour.&#xD;
&#xD;
          8. History or presence of cancer.&#xD;
&#xD;
          9. Difficulty with donating blood.&#xD;
&#xD;
         10. Difficulty in swallowing solids like tablets or capsules.&#xD;
&#xD;
         11. Systolic blood pressure less than 100 mm Hg or more than 140 mm Hg.&#xD;
&#xD;
         12. Diastolic blood pressure less than 60 mm Hg or more than 90 mm Hg.&#xD;
&#xD;
         13. Pulse rate less than 50/minute or more than 100/minute.&#xD;
&#xD;
         14. Oral temperature less than 95°F or more than 98.6°F.&#xD;
&#xD;
         15. Respiratory rate less than 12/minute or more than 20/minute&#xD;
&#xD;
         16. Subjects who have used any prescription medication, within 14 days of period 01 dosing&#xD;
             or OTC medication within 14 days of period 01 dosing.&#xD;
&#xD;
         17. Major illness during 3 months before screening.&#xD;
&#xD;
         18. Participation in a drug research study within past 3 months.&#xD;
&#xD;
         19. Donation of blood in the past 3 months before screening.&#xD;
&#xD;
         20. Subjects who have consumed xanthine-containing products (including caffeine,&#xD;
             theobromines, etc.) within 48 hours prior to period 01 dosing.&#xD;
&#xD;
         21. Subjects who have consumed food or beverages containing grapefruit or pomelo within 14&#xD;
             days prior to period 01 dosing.&#xD;
&#xD;
         22. Subjects who have used any drugs or substances known to be strong inhibitors of CYP&#xD;
             enzymes (formerly known as cytochrome P450 enzymes) within 28 days prior to the first&#xD;
             dose.&#xD;
&#xD;
         23. Subjects who have used any drugs or substances known to be strong inducers of CYP&#xD;
             enzymes (formerly known as cytochrome P450 enzymes) within 28 days prior to the first&#xD;
             dose.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dr. Dharmesh Domadia, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Veeda clinical research Pvt. Ltd., India</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Veeda clinical research Pvt. Ltd., India</name>
      <address>
        <city>Ahmedabad</city>
        <state>Gujrat</state>
        <zip>380 015</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>June 2010</verification_date>
  <study_first_submitted>June 2, 2010</study_first_submitted>
  <study_first_submitted_qc>June 2, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 3, 2010</study_first_posted>
  <last_update_submitted>June 11, 2010</last_update_submitted>
  <last_update_submitted_qc>June 11, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 14, 2010</last_update_posted>
  <responsible_party>
    <name_title>Mr. Indu Bhushan/Senior Director</name_title>
    <organization>Dr. Reddy's Laboratories Limited</organization>
  </responsible_party>
  <keyword>Bioequivalence</keyword>
  <keyword>Crossover</keyword>
  <keyword>Valacyclovir Hydrochloride</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Malnutrition</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Valacyclovir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

